Literature DB >> 22752641

Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.

Daisuke Iitaka1, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji.   

Abstract

A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy. The histopathological diagnosis was poorly differentiated squamous cell carcinoma, pT2N1M0 pStageIIB. After one course of postoperative adjuvant chemotherapy involving low-dose CDDP/5FU, a PET-CT scan obtained 12 months after surgery revealed a solitary liver metastasis in the S2 area. The patient then underwent five courses of docetaxel chemotherapy (80 mg/body, tri-weekly), and a partial response was observed. We also performed radiofrequency ablation (RFA), after which a complete response was observed. Twenty months after surgery, we detected local liver recurrence in the same position and performed additional RFA. Twenty-four months after surgery, a solitary lung metastasis was detected in the left S2 area and the patient was administered five additional courses of docetaxel therapy. Subsequently, PET-CT revealed growth of lung and liver tumors without recurrence in other areas. Twenty-nine months after surgery, we partially excised metastatic liver and lung tumors, and no subsequent recurrence has since been detected. The prognoses of patients who suffer from esophageal cancer organ recurrence are known to be extremely poor, and optimal therapeutic strategies for treating these patients have not been established. This long-term survival case suggests that multidisciplinary therapy for the treatment of liver and lung recurrence after esophagectomy is effective.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752641     DOI: 10.1007/s00595-012-0240-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  26 in total

1.  Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy.

Authors:  Y Nakajima; K Nagai; T Kawano; H Inoue; S Nara; Y Kumagai; T Iwai
Journal:  Hepatogastroenterology       Date:  2001 Nov-Dec

2.  Pattern of recurrence after oesophageal resection for cancer: clinical implications.

Authors:  S Y Law; M Fok; J Wong
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

3.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

4.  Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.

Authors:  Atsushi Shiozaki; Hisakazu Yamagishi; Hirosumi Itoi; Hitoshi Fujiwara; Shojiro Kikuchi; Kazuma Okamoto; Daisuke Ichikawa; Nobuaki Fuji; Toshiya Ochiai; Teruhisa Sonoyama; Yuji Ueda
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

5.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

6.  Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Yuichi Sanada; Shinji Osada; Kazuya Yamaguchi; Takao Takahashi
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-28       Impact factor: 3.333

7.  A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.

Authors:  K Muro; T Hamaguchi; A Ohtsu; N Boku; K Chin; I Hyodo; H Fujita; W Takiyama; T Ohtsu
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

Review 8.  Needlescopic ablation of small adrenal masses.

Authors:  Eric Lauer; Joseph J Del Pizzo; Jay D Raman
Journal:  Curr Urol Rep       Date:  2009-01       Impact factor: 3.092

Review 9.  Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed.

Authors:  F M Gómez; J Palussière; E Santos; T Tourdias; F Cornélis; V Sáiz; H Montes; O Eker
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

10.  [A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected].

Authors:  Yutaka Tokairin; Youichi Kumagai; Shigeru Yamazaki
Journal:  Gan To Kagaku Ryoho       Date:  2009-11
View more
  11 in total

1.  Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report.

Authors:  Atsuto Katano; Hideomi Yamashita; Keiichi Nakagawa
Journal:  Mol Clin Oncol       Date:  2017-10-04

2.  Treatment paradigms and survival outcomes in esophageal adenocarcinoma with liver metastasis: a retrospective cohort study using the SEER database.

Authors:  Jing Guo; Chang-Yong Tong; Jian-Guang Shi; Xin-Jian Li
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  The effect of tumor locations of esophageal cancer on the metastasis to liver or lung.

Authors:  Dashan Ai; Yun Chen; Qi Liu; Jiaying Deng; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Yang; Jun Jia; Zhiwei Sun; Chuanling Liu; Yanjie Xiao; Jing Yu; Feng Du; Xiaodong Zhang
Journal:  Cancer Manag Res       Date:  2020-03-24       Impact factor: 3.989

5.  Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer.

Authors:  Jing Xu; Donghui Lu; Li Zhang; Jian Li; Guoping Sun
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

6.  Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent.

Authors:  K Parry; E Visser; P S N van Rossum; N Haj Mohammad; J P Ruurda; R van Hillegersberg
Journal:  Ann Surg Oncol       Date:  2015-09-03       Impact factor: 5.344

Review 7.  The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.

Authors:  Dimitrios Schizas; Ioannis I Lazaridis; Demetrios Moris; Aikaterini Mastoraki; Lazaros-Dimitrios Lazaridis; Diamantis I Tsilimigras; Nikolaos Charalampakis; Theodore Liakakos
Journal:  World J Surg Oncol       Date:  2018-03-14       Impact factor: 2.754

8.  Successful Endoscopic Treatment of Post-esophagectomy Refractory Reflux Using OverStitch: The First Clinical Case.

Authors:  Hirotsugu Nagase; Makoto Yamasaki; Yoshitomo Yanagimoto; Takashi Kanemura; Shigeyoshi Higashi; Kota Momose; Ryo Kato; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Hiroshi Miyata; Shuji Takiguchi; Masaki Mori; Yuichiro Doki; Kiyokazu Nakajima
Journal:  Clin Med Insights Gastroenterol       Date:  2018-07-03

9.  Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report.

Authors:  Kosuke Hirose; Hiroshi Saeki; Yuichiro Nakashima; Tomohiro Kamori; Yoshiaki Fujimoto; Tetsuro Kawazoe; Hiroya Matsuoka; Yasuhiro Haruta; Shun Sasaki; Tomoko Jogo; Qingjiang Hu; Yasuo Tsuda; Koji Ando; Eiji Oki; Ryuzo Hiratsuka; Yoshinao Oda; Masaki Mori
Journal:  Surg Case Rep       Date:  2019-05-03

10.  Hepatic Metastasis in Newly Diagnosed Esophageal Cancer: A Population-Based Study.

Authors:  Huawei Li; Shengqiang Zhang; Jida Guo; Linyou Zhang
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.